NASDAQ · SEER
Healthcare · Biotechnology
$1.90
Up+$0.00 (+0.00%)
Updated Sep 16, 2026, 10:51 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SEER closed at $1.90 after 20 trading sessions, down 5.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1.90 | $1.92 | $1.89 | $1.90 | 181.45K |
| Sep 14, 2026 | $1.94 | $1.945 | $1.90 | $1.91 | 161.27K |
| Sep 11, 2026 | $1.94 | $1.955 | $1.94 | $1.95 | 84.22K |
| Sep 10, 2026 | $1.94 | $1.97 | $1.93 | $1.93 | 152.53K |
| Sep 9, 2026 | $1.94 | $1.96 | $1.93 | $1.94 | 147.7K |
| Sep 8, 2026 | $1.94 | $1.98 | $1.932 | $1.95 | 193.74K |
| Sep 4, 2026 | $1.93 | $1.96 | $1.93 | $1.95 | 68.81K |
| Sep 3, 2026 | $1.96 | $1.97 | $1.93 | $1.94 | 67.75K |
| Sep 2, 2026 | $1.94 | $2.005 | $1.94 | $1.98 | 121.19K |
| Sep 1, 2026 | $1.96 | $1.98 | $1.93 | $1.94 | 411.46K |
| Aug 31, 2026 | $1.98 | $1.999 | $1.95 | $1.96 | 145.12K |
| Aug 28, 2026 | $2.01 | $2.0185 | $1.98 | $1.98 | 156.09K |
| Aug 27, 2026 | $2.00 | $2.04 | $2.00 | $2.01 | 102.78K |
| Aug 26, 2026 | $2.03 | $2.04 | $2.005 | $2.02 | 124.5K |
| Aug 25, 2026 | $2.05 | $2.0811 | $2.03 | $2.04 | 100.64K |
| Aug 24, 2026 | $2.05 | $2.065 | $2.02 | $2.04 | 207.12K |
| Aug 21, 2026 | $2.01 | $2.05 | $2.01 | $2.03 | 117.1K |
| Aug 20, 2026 | $2.04 | $2.07 | $2.01 | $2.02 | 176.52K |
| Aug 19, 2026 | $2.00 | $2.08 | $2.00 | $2.05 | 182.54K |
| Aug 18, 2026 | $2.02 | $2.035 | $2.01 | $2.02 | 258.29K |
The latest Smart Investors Daily articles mentioning SEER.
SEER research
Company profile and research snapshot.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 4, 2026 | Canaccord Genuity | Buy | — |
| Aug 13, 2024 | Morgan Stanley | Equal-Weight | — |
| Mar 5, 2024 | Morgan Stanley | Equal-Weight | — |
| Feb 21, 2023 | Morgan Stanley | Equal-Weight | — |
| Jan 4, 2023 | B of A Securities | Underperform | — |
No generated briefing is available yet.
Yahoo · Sep 4, 2026
HOUSTON, September 04, 2026--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER), today issued the following open letter to director Meeta Gulyani.
SeekingAlpha · Aug 11, 2026
Seer, Inc. (SEER) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDTCompany ParticipantsOmid Farokhzad - Founder, CEO, & Chair of the Board of...
SeekingAlpha · Aug 11, 2026
2026-08-11. The following slide deck was published by Seer, Inc.
Benzinga · Aug 11, 2026
Seer (NASDAQ:SEER) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.27) by 14.81 percent. This is a 6.06 percent increase over losses of $(0.33) per share from the same
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SEER.
